Current autoimmune treatments are largely systemic, which raise the risk of infection and malignancy, and limit combination regimes. Third Arc Bio addresses the shortcomings of current autoimmune treatments with our ARCTag Platform, which localizes immune modulating molecules to the site of disease.
Two Innovative Platforms: Solid Tumors and Inflammatory & Immunology (I&I)
By tailoring approaches for each disease mechanism, Third Arc Bio develops immune cell-engaging antibodies that modulate T cell activity at the site of disease, to transform the treatment paradigm for both oncology and I&I diseases.
Oncology: ARCStim Platform
Next-gen T Cell Engagers to Transform Solid Tumor Therapy
Tumor Specificity
Precision targeting at the epitope level for tumor specificity
Conditional Activation
Tumor-dependent activation for improved therapeutic index
Signal 2 Costimulation
Amplifying T cell activation for deep and durable responses
I&I: ARCTag Platform
Tissue-specific Suppression of Immune Cells
We continue to expand a compelling pipeline with next-generation solid tumor and I&I multispecific programs.
